Events

LSX World Congress w/ Jackie Hunter

Drug Discovery and Development in the Era of AI and Analytics

The life science sector has struggled for years with expensive, inefficient drug discovery and high failure rates in drug development. Now, new technologies like artificial intelligence, machine learning, and data analytics promise to revolutionise biopharma R&D with in-silico drug design, sophisticated analysis of highly complex data sets, and an accelerated path through the clinic and to market. But what is the reality on the ground behind the buzz? Just how remote is the R&D model promoted by AI evangelists, and what are the major hurdles that R&D teams and innovators still must overcome if that model is to become reality? A panel of biopharma R&D transformers discuss the potential of artificial intelligence and data-driven technologies to create a new digital R&D paradigm.

  • “Necessity is the mother of invention” – why is AI so valuable to R&D teams?
  • How successful has innovation in the R&D space been thus far?
  • Commercialising data-driven drug discovery and development technologies

Register here →

Featuring:

Jackie Hunter | Board Member, BenevolentAI

Abraham Heifets | CEO Atomwise

Martin-Immanuel Bittner | CEO, Arctoris

Nick Scott-Ram | Chief of Strategic Development, Sensyne Health

Moderator: Bill Aronson | COO, Artificial Intelligence Research Group


Jackie Hunter

Board Director of BenevolentAI

Jackie Hunter is a Board Director of BenevolentAI.  Jackie has over thirty years of experience in the bioscience research sector, working across academia and industry including leading neurology and gastrointestinal drug discovery and early clinical development for GlaxoSmithKline. She founded OI Pharma Partners in 2010 to support the life science sector in harnessing the power of open innovation and most recently was Chief Executive of the Biotechnology and Biological Sciences Research Council. She holds a personal chair from St George's Hospital Medical School, which was awarded in recognition of her contribution to bioscience research. In 2010 she was awarded a CBE in the Queen's Birthday Honours list for Services to the Pharmaceutical Industry.

More Posts

You Might Also Like

Blog
Tech Nation Visa: the gateway to world-leading UK tech jobs
Drawing attention to the Tech Nation Visa, a great initiative that enables the brightest international talent to live and work in the UK.
Feb 19, 2021
News
BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial
A molecule designed and developed by BenevolentAI to treat mild to moderate Atopic Dermatitis has entered clinical trials.
Feb 11, 2021
News
BenevolentAI and AstraZeneca achieve collaboration milestone with novel AI-generated chronic kidney disease target
BenevolentAI and AstraZeneca hit collaboration milestone with an AI-generated CKD target from the partnership entering AstraZeneca’s portfolio.
Jan 27, 2021
News
ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients
Peer-reviewed data from the ACTT-2 further validate BenevolentAI’s hypothesis for baricitinib as a potential COVID-19 treatment.
Jan 15, 2021
Blog
Joanna Shields speaks at the Global Partnership on Artificial Intelligence
BenevolentAI CEO Joanna Shields opened the final plenary of the Global Partnership on Artificial Intelligence (GPAI) summit with a powerful message on the future of AI.
Dec 11, 2020
Blog
BenevolentAI wins Innovation Award at 2020 Scrip Awards
BenevolentAI wins the Innovation Award at the prestigious 2020 Scrip Awards for our work in artificial intelligence applied drug discovery.
Dec 11, 2020